biosimilars

biosimilars

美 　英

• 網絡生物仿制藥；生物相似藥；生技仿制藥

例句

And he supports efforts to encourage "biosimilars" , a form of generic rival to biotech drugs, which the industry hates.

同時，不顧制藥業的反對，麥凱恩還鼓勵研制生物仿制藥——這種基因藥物是生化藥物的競爭對手。

It will spend about half of the 2. 1 trillion won budget on developing biosimilars and use the other half to build factories, he said.

他說，三星集團將花費2100萬韓元投資中的一般用于開發生物仿制藥，而另一半用于建設生產廠。

There's a lot of talk about biosimilars but from my view there will also be a lot of wait-and-see.

有關生物仿制藥品的傳言甚多，但在我看來，許多都是在觀望。

Biosimilars are generic impersonations (although not identical copies) of biotech drugs.

生物仿制制藥是對生物技術制藥進行的非專利仿制（盡管不是完全一致的復制）。

It is actually a very cost-efficient way for pharma companies to differentiate themselves from the biosimilars.

對于制藥公司來說，這可以很劃算地讓他們與一般的生物仿制藥作出區分。

This is part of a new strategy to become a "one-stop shop" for biosimilars, explains David Simmons of Pfizer.

來自輝瑞制藥的戴維西蒙斯說這是組成生物仿制制藥“一站式商店”這個新戰略的一部分。

Cipla, an Indian generics maker, and China's Desano Pharma are also getting into the biosimilars business.

印度非專利藥品廠商Cipla和中國迪賽諾醫藥發展有限公司也正在進入仿生物藥品業務。

Samsung Group may also set up another joint venture to make biosimilars this year, Kim said.

金泰韓說，三星集團今年還會再成立一家合資公司生產生物仿制藥。

First, they are much harder to copy, so generic equivalents (called "biosimilars" ) will be slow in coming.

首先，該行業技術更難效仿，通用一個藥名的制劑（生物仿制藥）很難出現。

Biosimilars are a hot new area.

仿生物藥品是新型熱門領域。